Publication de 6 numéros par an
ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502
Indexed in
Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
RÉSUMÉ
Hepatocellular carcinoma (HCC) is one of the leading causes of death associated with cancer. Various molecular mechanisms are involved in HCC development. Alterations in these molecular mechanisms include chromosomal instability, gene mutations, and variations in protein expressions. A number of cell signaling pathways that are associated with the occurrence of apoptosis, cell proliferation, and angiogenesis provide new prospects for the development of HCC treatments. Newly designed, potential therapeutic regimens target specific receptors, kinases, and vital proteins. Sorafenib is the only FDA-approved drug for HCC treatment, and it has been found that the complex genomic aberrations in HCC can be overcome using combination therapy. For example, therapeutic benefits have been gained using sorafenib with doxorubicin, oxaliplatin, cisplatin, and monoclonal antibodies. In addition, elumetinib, carbozantinib, and refametinib may be effective when used in combination with sorafenib. Drugs that target several signaling pathways have shown promising results in phase 3 clinical trials, and clinical studies using these drugs have changed the management strategy for HCC, particularly with the use of combination therapeutic regimens. Such research has improved the current standards of care and influenced clinical decision making.
-
Allen Rebecca, Li Daneng, Hepatocellular Carcinoma, in Oncology in the Precision Medicine Era, 2020. Crossref
-
Ren Feng, Wu Kaixuan, Yang Yun, Yang Yingying, Wang Yuxia, Li Jian, Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1α Expression, Frontiers in Pharmacology, 11, 2020. Crossref
-
Zhong Xiao‑Zhu , Deng Yun , Chen Gang , Yang Hong , Investigation of the clinical significance and molecular mechanism of miR‑21‑5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation, Oncology Letters, 2018. Crossref
-
Akhtar Muhammad Furqan, Saleem Ammara, Rasul Azhar, Faran Ashraf Baig Mirza Muhammad, Bin-Jumah May, Abdel Daim Mohamed M., Anticancer natural medicines: An overview of cell signaling and other targets of anticancer phytochemicals, European Journal of Pharmacology, 888, 2020. Crossref
-
Liu Zhao, Sun Jiuzheng, Li Chuanzhi, Xu Liyou, Liu Jun, MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling, BMC Cancer, 21, 1, 2021. Crossref
-
Saleem Mohammad, Schini-Kerth Valerie B., Hussain Khalid, Khalid Syed H., Asif Muhammad, Alhosin Mahmoud, Akhtar Muhammad F., Ahmad Bashir, Raza Atif, Mahrukh , Molecular Mechanisms Responsible for In Vitro Cytotoxic Attributes of Conyza bonariensis Extract against Lymphoblastic Leukaemia Jurkat Cells, Anti-Cancer Agents in Medicinal Chemistry, 22, 9, 2022. Crossref